A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
Van Den Neste, Eric, André, Marc, Gastinne, Thomas, Stamatoullas, Aspasia, Haioun, Corinne, Belhabri, Amine, Reman, Oumedaly, Casasnovas, Olivier, Ghesquieres, Hervé, Verhoef, Gregor, Claessen, Marie-José, Poirel, Hélène A, Copin, Marie-Christine, Dubois, Romain, Vandenberghe, Peter, Stoian, Ioanna-Andrea, Cottereau, Anne S, Bailly, Sarah, Knoops, Laurent, Morschhauser, Franck
Published in Haematologica (Roma) (01.05.2018)
Published in Haematologica (Roma) (01.05.2018)
Get full text
Journal Article
A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
Van Den Neste, Eric W, Andre, Marc, Gastinne, Thomas, Stamatoullas, Aspasia, Haioun, Corinne, Belhabri, Amine, Reman, Oumedaly, Casasnovas, Olivier, Ghesquieres, Herve, Verhoef, Gregor, Claessen, Marie-José, Poirel, Hélène A, Copin, Marie-Christine, Dubois, Romain, Vandenberghe, Peter, Stoian, Ioanna-Andrea, Cottereau, Anne Ségolène, Knoops, Laurent, Morschhauser, Franck
Published in Blood (02.12.2016)
Published in Blood (02.12.2016)
Get full text
Journal Article